ClinicalTrials.govpublic full text
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
non-small cell lung cancer, lung, xl184 (cabozantinib), kif5b/ret positive, ret fusion positive, 12-097, genotypes: ros1 or ntrk fusions or increased met or axl activity, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 831531
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.